A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

Autor: Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. tosshimi@ncc.go.jp., Kuboki Y; National Cancer Center Hospital East, Chiba, Japan., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yanai T; Takeda Pharmaceutical Company Limited, Osaka, Japan., Faller DV; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Dobler L; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Gupta N; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Sedarati F; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Kim KP; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jazyk: angličtina
Zdroj: Targeted oncology [Target Oncol] 2022 Jan; Vol. 17 (1), pp. 15-24. Date of Electronic Publication: 2021 Nov 29.
DOI: 10.1007/s11523-021-00855-w
Abstrakt: Background: Sapanisertib is an oral, highly selective inhibitor of mammalian target of rapamycin complexes 1 and 2.
Objective: The aim of this study was to assess the safety, tolerability, pharmacokinetics, preliminary efficacy, and to establish the recommended phase 2 dose (RP2D) of sapanisertib.
Patients and Methods: In this dose-escalation and expansion study, East Asian patients with nonhematologic malignancies received increasing sapanisertib doses once-daily (QD; starting at 2 mg) or once-weekly (QW; starting at 20 mg) in 28-day cycles.
Results: Among 28 patients (QD dosing, n = 22; QW dosing, n = 6), three dose-limiting toxicities were reported (stomatitis [n = 2], gastrointestinal inflammation, gingivitis, and acute myocardial infarction [all n = 1]), all in the 4 mg QD cohort. The RP2D of sapanisertib was 3 mg QD. The most common adverse events were stomatitis (64%), nausea (50%), and decreased appetite (50%) in the QD arm, and nausea (100%), blood alkaline phosphatase increased (67%), and hyperglycemia (67%) in the QW arm. The T max of sapanisertib was ~ 0.5-2.6 h and the T 1/2 was ~ 5.9-7.6 h. Three patients achieved stable disease for ≥ 6 months (1 each in 3 mg QD, 4 mg QD and 20 mg QW cohorts, respectively); the clinical benefit rate was 45% and 67% in the QD and QW arms, respectively.
Conclusions: The RP2D of sapanisertib in East Asian patients (3 mg QD) was lower than in Western patients (4 mg QD), but the pharmacokinetics and safety profiles were similar. Sapanisertib was well tolerated and showed moderate anti-tumor effects in heavily pretreated patients with nonhematologic malignancies.
Nct Number: NCT03370302; Registered December 7, 2017.
(© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: